Nicole C Lorona1,2, Linda S Cook3, Mei-Tzu C Tang4, Deirdre A Hill3, Charles L Wiggins3, Christopher I Li4,5. 1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, Seattle, WA, M4-C308, USA. nlorona@fredhutch.org. 2. Department of Epidemiology, University of Washington, Seattle, WA, USA. nlorona@fredhutch.org. 3. Department of Internal Medicine, University of New Mexico and the University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA. 4. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, Seattle, WA, M4-C308, USA. 5. Department of Epidemiology, University of Washington, Seattle, WA, USA.
Abstract
PURPOSE: Antihypertensives are commonly prescribed medications and their effect on breast cancer recurrence and mortality is not clear, particularly among specific molecular subtypes of breast cancer: luminal, triple-negative (TN), and HER2-overexpressing (H2E). METHODS: A population-based prospective cohort study of women aged 20-69 diagnosed with a first primary invasive breast cancer between 2004 and 2015 was conducted in the Seattle, Washington and Albuquerque, New Mexico greater metropolitan areas. Multivariable-adjusted Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for risks of breast cancer recurrence, breast cancer-specific mortality, and all-cause mortality associated with hypertension and antihypertensives. RESULTS: In this sample of 2,383 luminal, 1,559 TN, and 615 H2E breast cancer patients, overall median age was 52 (interquartile range, 44-60). Hypertension and current use of antihypertensives were associated with increased risks of all-cause mortality in each subtype. Current use of angiotensin-converting enzyme inhibitors was associated with increased risks of both recurrence and breast cancer-specific mortality among luminal patients (HR: 2.5; 95% CI: 1.5, 4.3 and HR: 1.9; 95% CI: 1.2, 3.0, respectively). Among H2E patients, current use of calcium channel blockers was associated with an increased risk of breast cancer-specific mortality (HR: 1.8; 95% CI: 0.6, 5.4). CONCLUSION: Our findings suggest that some antihypertensive medications may be associated with adverse breast cancer outcomes among women with certain molecular subtypes. Additional studies are needed to confirm these findings.
PURPOSE: Antihypertensives are commonly prescribed medications and their effect on breast cancer recurrence and mortality is not clear, particularly among specific molecular subtypes of breast cancer: luminal, triple-negative (TN), and HER2-overexpressing (H2E). METHODS: A population-based prospective cohort study of women aged 20-69 diagnosed with a first primary invasive breast cancer between 2004 and 2015 was conducted in the Seattle, Washington and Albuquerque, New Mexico greater metropolitan areas. Multivariable-adjusted Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for risks of breast cancer recurrence, breast cancer-specific mortality, and all-cause mortality associated with hypertension and antihypertensives. RESULTS: In this sample of 2,383 luminal, 1,559 TN, and 615 H2E breast cancer patients, overall median age was 52 (interquartile range, 44-60). Hypertension and current use of antihypertensives were associated with increased risks of all-cause mortality in each subtype. Current use of angiotensin-converting enzyme inhibitors was associated with increased risks of both recurrence and breast cancer-specific mortality among luminal patients (HR: 2.5; 95% CI: 1.5, 4.3 and HR: 1.9; 95% CI: 1.2, 3.0, respectively). Among H2E patients, current use of calcium channel blockers was associated with an increased risk of breast cancer-specific mortality (HR: 1.8; 95% CI: 0.6, 5.4). CONCLUSION: Our findings suggest that some antihypertensive medications may be associated with adverse breast cancer outcomes among women with certain molecular subtypes. Additional studies are needed to confirm these findings.
Authors: Joshua VanHouten; Catherine Sullivan; Caroline Bazinet; Tom Ryoo; Robert Camp; David L Rimm; Gina Chung; John Wysolmerski Journal: Proc Natl Acad Sci U S A Date: 2010-06-04 Impact factor: 11.205
Authors: Sara Raimondi; Edoardo Botteri; Elisabetta Munzone; Carlo Cipolla; Nicole Rotmensz; Andrea DeCensi; Sara Gandini Journal: Int J Cancer Date: 2016-03-12 Impact factor: 7.396
Authors: Sunil M Shah; Iain M Carey; Christopher G Owen; Tess Harris; Stephen Dewilde; Derek G Cook Journal: Br J Clin Pharmacol Date: 2011-07 Impact factor: 4.335
Authors: Nadia Howlader; Lynn A G Ries; Angela B Mariotto; Marsha E Reichman; Jennifer Ruhl; Kathleen A Cronin Journal: J Natl Cancer Inst Date: 2010-10-11 Impact factor: 13.506
Authors: Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist Journal: Breast Cancer Res Treat Date: 2014-02-21 Impact factor: 4.872
Authors: Edoardo Botteri; Elisabetta Munzone; Nicole Rotmensz; Carlo Cipolla; Vincenzo De Giorgi; Barbara Santillo; Arnaldo Zanelotti; Laura Adamoli; Marco Colleoni; Giuseppe Viale; Aron Goldhirsch; Sara Gandini Journal: Breast Cancer Res Treat Date: 2013-08-03 Impact factor: 4.872
Authors: Chris R Cardwell; Úna C Mc Menamin; Blánaid M Hicks; Carmel Hughes; Marie M Cantwell; Liam J Murray Journal: BMC Med Date: 2014-02-13 Impact factor: 8.775
Authors: Desmond G Powe; Melanie J Voss; Kurt S Zänker; Hany O Habashy; Andrew R Green; Ian O Ellis; Frank Entschladen Journal: Oncotarget Date: 2010-11
Authors: Elena Pera; Elke Kaemmerer; Michael J G Milevskiy; Kunsala T D S Yapa; Jake S O'Donnell; Melissa A Brown; Fiona Simpson; Amelia A Peters; Sarah J Roberts-Thomson; Gregory R Monteith Journal: Cancer Cell Int Date: 2016-03-31 Impact factor: 5.722